{"pmid":32459882,"title":"Comment on \"Is the type of diabetes treatment relevant to outcome of COVID-19?\"","text":["Comment on \"Is the type of diabetes treatment relevant to outcome of COVID-19?\"","J Diabetes","Pal, Rimesh","Banerjee, Mainak","32459882"],"journal":"J Diabetes","authors":["Pal, Rimesh","Banerjee, Mainak"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32459882","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/1753-0407.13069","keywords":["anti-diabetic drugs","anti-inflammatory","covid-19","hydroxychloroquine","pioglitazone"],"weight":0,"_version_":1668141322621419520,"score":9.490897,"similar":[{"pmid":32305399,"pmcid":"PMC7162752","title":"COVID-19 and diabetes management: What should be considered?","text":["COVID-19 and diabetes management: What should be considered?","Diabetes Res Clin Pract","Ceriello, Antonio","Stoian, Anca Pantea","Rizzo, Manfredi","32305399"],"journal":"Diabetes Res Clin Pract","authors":["Ceriello, Antonio","Stoian, Anca Pantea","Rizzo, Manfredi"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32305399","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.diabres.2020.108151","keywords":["covid-19","cardiovascular disease","dpp4","diabetes","glp-1ra","hydroxychloroquine","pioglitazone","sglt-2"],"topics":["Treatment"],"weight":1,"_version_":1666138493373382656,"score":78.37721},{"pmid":32382358,"pmcid":"PMC7204191","title":"COVID-19 and Diabetes Mellitus: May Old Anti-diabetic Agents Become the New Philosopher's Stone?","text":["COVID-19 and Diabetes Mellitus: May Old Anti-diabetic Agents Become the New Philosopher's Stone?","Corona virus infectious disease (COVID-19) is a new pandemic. In subjects with diabetes mellitus, infection may be more frequent and severe. We discuss the potential contribution of two traditional oral antidiabetic agents, metformin and pioglitazone, to the improvement of liver injury in COVID-19. Clearly, further experience is needed to shed light on these hypotheses.","Diabetes Ther","Penlioglou, Theano","Papachristou, Stella","Papanas, Nikolaos","32382358"],"abstract":["Corona virus infectious disease (COVID-19) is a new pandemic. In subjects with diabetes mellitus, infection may be more frequent and severe. We discuss the potential contribution of two traditional oral antidiabetic agents, metformin and pioglitazone, to the improvement of liver injury in COVID-19. Clearly, further experience is needed to shed light on these hypotheses."],"journal":"Diabetes Ther","authors":["Penlioglou, Theano","Papachristou, Stella","Papanas, Nikolaos"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32382358","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s13300-020-00830-0","keywords":["antidiabetic agents","corona virus infectious disease","diabetes mellitus","metformin","pioglitazone","treatment"],"e_drugs":["Pioglitazone","Metformin"],"topics":["Treatment"],"weight":1,"_version_":1666419683255910400,"score":62.719788},{"pmid":32353193,"title":"Is the type of diabetes treatment relevant to outcome of COVID-19?","text":["Is the type of diabetes treatment relevant to outcome of COVID-19?","J Diabetes","Bloomgarden, Zachary","32353193"],"journal":"J Diabetes","authors":["Bloomgarden, Zachary"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32353193","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/1753-0407.13047","topics":["Treatment"],"weight":1,"_version_":1666138495643549697,"score":57.42633},{"pmid":32373183,"pmcid":"PMC7192209","title":"Chloroquine and hydroxychloroquine in the context of COVID-19.","text":["Chloroquine and hydroxychloroquine in the context of COVID-19.","Chloroquine and closely related structural analogs, employed initially for the treatment of malaria, are now gaining worldwide attention due to the rapidly spreading pandemic caused by severe acute respiratory syndrome-coronavirus-2, named coronavirus disease (COVID) of 2019 (COVID-19). Although much of this attention has a mechanistic basis, the hard efficacy data for chloroquine/hydroxychloroquine in the management of the clinical syndrome of COVID-19 have been limited thus far. This review aims to present the available in vitro and clinical data for the role of chloroquine/hydroxychloroquine in COVID-19 and attempts to put them into perspective, especially in relation to the different risks/benefits particular to each patient who may require treatment.","Drugs Context","Shukla, Ashutosh M","Archibald, Lennox K","Shukla, Aparna Wagle","Mehta, Hiren J","Cherabuddi, Kartikeya","32373183"],"abstract":["Chloroquine and closely related structural analogs, employed initially for the treatment of malaria, are now gaining worldwide attention due to the rapidly spreading pandemic caused by severe acute respiratory syndrome-coronavirus-2, named coronavirus disease (COVID) of 2019 (COVID-19). Although much of this attention has a mechanistic basis, the hard efficacy data for chloroquine/hydroxychloroquine in the management of the clinical syndrome of COVID-19 have been limited thus far. This review aims to present the available in vitro and clinical data for the role of chloroquine/hydroxychloroquine in COVID-19 and attempts to put them into perspective, especially in relation to the different risks/benefits particular to each patient who may require treatment."],"journal":"Drugs Context","authors":["Shukla, Ashutosh M","Archibald, Lennox K","Shukla, Aparna Wagle","Mehta, Hiren J","Cherabuddi, Kartikeya"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32373183","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.7573/dic.2020-4-5","keywords":["covid-19","sars-cov-2","anti-inflammatory","antimalarial","antiviral","chloroquine","hydroxychloroquine","immunomodulatory","pandemic"],"e_drugs":["Hydroxychloroquine","Chloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666138496345047040,"score":52.19686},{"pmid":32470851,"pmcid":"PMC7214326","title":"Role of oxidized LDL-induced \"trained macrophages\" in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesis.","text":["Role of oxidized LDL-induced \"trained macrophages\" in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesis.","BACKGROUND AND AIMS: Older adults and people who have cardiovascular disorders (their common pathogenetic mechanism is progressive atherosclerosis) are at higher risk for severe illness from COVID-19 (coronavirus disease 2019). Their common pathogenetic mechanism is progressive atherosclerosis in which oxLDL (oxidized LDL) plays major role. Receptor-mediated uptake of oxLDL by the monocyte-derived macrophages activates the long-term epigenetic reprogramming of innate immunity, which is termed \"trained immunity.\" The aim of this work is to investigate the mechanisms and treatment possibilities that can control the activities of these specific macrophages. METHODS: Search in Medline and PubMed relevant articles on the trained immunity and cytokine storm of COVID-19. RESULTS AND CONCLUSIONS: When oxLDL-trained macrophages encounter SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) in the lung, it causes unregulated cytokine secretion, leading to the alveolar damage. Therefore, blocking macrophage training by pioglitazone, a thiazolidinedione, could control the hyperactivation that the virus would trigger.","Diabetes Metab Syndr","Erol, Adnan","32470851"],"abstract":["BACKGROUND AND AIMS: Older adults and people who have cardiovascular disorders (their common pathogenetic mechanism is progressive atherosclerosis) are at higher risk for severe illness from COVID-19 (coronavirus disease 2019). Their common pathogenetic mechanism is progressive atherosclerosis in which oxLDL (oxidized LDL) plays major role. Receptor-mediated uptake of oxLDL by the monocyte-derived macrophages activates the long-term epigenetic reprogramming of innate immunity, which is termed \"trained immunity.\" The aim of this work is to investigate the mechanisms and treatment possibilities that can control the activities of these specific macrophages. METHODS: Search in Medline and PubMed relevant articles on the trained immunity and cytokine storm of COVID-19. RESULTS AND CONCLUSIONS: When oxLDL-trained macrophages encounter SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) in the lung, it causes unregulated cytokine secretion, leading to the alveolar damage. Therefore, blocking macrophage training by pioglitazone, a thiazolidinedione, could control the hyperactivation that the virus would trigger."],"journal":"Diabetes Metab Syndr","authors":["Erol, Adnan"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470851","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.dsx.2020.05.007","keywords":["covid-19","macrophage","pioglitazone","oxldl"],"locations":["Medline"],"e_drugs":["2,4-thiazolidinedione","Pioglitazone"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668420887181787136,"score":48.147835}]}